Eli Lilly Japan Obtains Additional Approval for Gemzar Injection.
The agent will now be available for the treatment of biliary tract cancer.
Initially approved in Japan in March 1999, Gemzar is currently indicated for the treatments of non-small cell lung cancer and pancreatic cancer.
The company expects that Gemzar, with its superior response rate and reduced side effects, will be an optimal choice for patients with biliary tract cancer.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jul 12, 2006|
|Previous Article:||Hitachi High-Technologies Launches Mask Design Data Measuring System.|
|Next Article:||Toray Ireeve Releases Ultrasonic Electric Toothbrush.|